KEGG   DRUG: D04489Help
Entry
D04489                      Drug                                   

Name
Ibritumomab tiuxetan (genetical recombination) (JAN);
Ibritumomab tiuxetan (USAN/INN);
Zevalin (TN)
Product
Activity
Antineoplastic [monoclonal antibody]
Remark
Therapeutic category: 
ATC code: 
Comment
Zevalin (TN) (Yttrium-labeled ibritumomab tiuxetan) is used for the treatment of non-Hodgkin's B-cell lymphoma, co-administrated with rituximab.
anti-CD20 monoclonal antibody
Target
CD20 [HSA:931] [KO:K06466]
  Pathway
hsa04640  Hematopoietic cell lineage  
 
Interaction
Genomic biomarker: CD20 [HSA:931]
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 V VARIOUS
  V10 THERAPEUTIC RADIOPHARMACEUTICALS
   V10X OTHER THERAPEUTIC RADIOPHARMACEUTICALS
    V10XX Various therapeutic radiopharmaceuticals
     V10XX02 Ibritumomab tiuxetan (90Y)
      D04489  Ibritumomab tiuxetan (genetical recombination) (JAN); Ibritumomab tiuxetan (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D04489  Ibritumomab tiuxetan (genetical recombination) (JAN); Ibritumomab tiuxetan (USAN/INN)
  43  Radioactive drugs
   430  Radioactive drugs
    4300  Radioactive drugs
     D04489  Ibritumomab tiuxetan (genetical recombination) (JAN); Ibritumomab tiuxetan (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Others
  Cellular antigens
   CD20
    Ibritumomab tiuxetan
     D04489  Ibritumomab tiuxetan (genetical recombination) (JAN); Ibritumomab tiuxetan (USAN/INN)
Antineoplastics [BR:br08308]
 Molecularly targeted agents
  Monoclonal antibody
   Ibritumomab tiuxetan
    D04489  Ibritumomab tiuxetan (genetical recombination) (JAN); Ibritumomab tiuxetan (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
206181-63-7
PubChem: 
DrugBank: 
NIKKAJI: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system